Product Wiki · Recalls · EU Safety Gate (RAPEX)

First Generation 5 — recall A12/03066/24

EU Safety Gate (RAPEX) · Germany · 2024-11-08 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/03066/24
Date of alert
2024-11-08
Country / jurisdiction
Germany
Risk level
Serious risk
Risk type
Chemical
Brand
I AM INK
Product category
Chemical products
Product type
Tattoo ink
Reported risk: Das Produkt weist eine übermäßige Konzentration von Formaldehyd auf (Messwert: 0,012 %). Formaldehyd ist ein Hautsensibilisator und kann allergische Reaktionen auslösen und Krebs verursachen. Das Produkt entspricht nicht der REACH-Verordnung.
Action taken by the authority
Type of economic operator taking notified measure
Distributor
Category of measure
Withdrawal of the product from the market
Date of entry into force
26/08/2024
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): First Generation 5

Risk Description (original English): The product has an excessive concentration of formaldehyde (measured value: 0.012 %). Formaldehyde is a skin sensitiser and can trigger allergic reactions and may cause cancer.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10080176

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.